FOR INVESTORS
Before adding capital, advice or pressure, know what is actually blocking the company.
Portfolio Commercial Review helps investors, accelerators and venture studios distinguish weak commercial evidence from weak execution, unclear positioning, founder bottlenecks and premature fundraising narratives.
Portfolio companies rarely fail because nobody is working hard. They fail because the next commitment rests on assumptions nobody has made explicit.
Which customer matters? Is the problem urgent? Are pilots real traction? Is the fundraising story supported by evidence? Is the founder carrying too much of the operating system personally?
THE DANGEROUS MIDDLE
Activity without decision-grade evidence.
Many early-stage technology companies are active. They have demos, pilots, product work, investor updates, customer conversations and a plausible story.
But activity can hide the real issue.
- Polite customer interest is treated as traction.
- Pilots continue without clear success criteria.
- Fundraising narratives run ahead of commercial evidence.
- Founders receive more advice but not more clarity.
- Board meetings create pressure but not sharper decisions.
- More capital risks buying time without resolving the uncertainty.
Use this before the next portfolio commitment.
Capital decisions
Bridge funding, follow-on decisions or continuation choices where more money may only extend ambiguity.
Portfolio support
When several companies are busy but stuck and the fund needs to decide where operating help should go.
Readiness moments
Before accelerator demo day, investor-readiness work, venture studio prioritisation or board discussions where progress is unclear.
For each company, the review identifies five things.
- The primary decision
What decision is the company avoiding, delaying or making implicitly? - The commercial assumption carrying the plan
What must be true for the next quarter, raise or expansion to make sense? - The evidence quality
What is fact, interpretation, weak signal or still missing?
- The actual bottleneck
Is the issue market, proposition, buyer urgency, sales motion, product readiness, founder bandwidth, cadence or investor narrative? - The recommended next intervention
Decision Review, Evidence-to-Action Sprint, embedded support, founder coaching, investor-readiness work or no intervention yet.
What the investor receives
Portfolio Risk Map
A cross-company view of where commercial and operating risk sits.
Company Decision Briefs
One concise brief per company: decision, assumptions, evidence, bottleneck and recommended next step.
Evidence Quality Assessment
Which companies have evidence strong enough to justify the next commitment, and which do not.
Intervention Recommendation
Where to spend operating support, where to wait, where to narrow, and where more capital would be premature.
Investor Debrief
A working session with the fund or programme team to discuss patterns, priorities and next actions.
SAMPLE OUTPUT
What a Portfolio Risk Map can look like
A useful portfolio review does not end with general advice. It should make the real constraint visible across companies.
WEAK EVIDENCE
Company A · Pilot conversion
Primary uncertainty: will customer interest convert into operational pilots?
Bottleneck: buyer urgency.
Next move: Commercial Decision Review.
MODERATE EVIDENCE
Company B · Raise readiness
Primary uncertainty: can the commercial case withstand investor scrutiny?
Bottleneck: milestone logic.
Next move: Evidence-to-Action Sprint.
STRONG EVIDENCE
Company C · Execution
Primary uncertainty: can the team carry the decision without the founder as system?
Bottleneck: founder coordination load.
Next move: Embedded Strategic Operator.
INSUFFICIENT EVIDENCE
Company D · Market focus
Primary uncertainty: which ICP deserves the next quarter?
Bottleneck: ICP too broad.
Next move: narrow or stop expansion.
Format
4–6 companies
Focused enough to go deep. Broad enough to show portfolio patterns.
2–3 weeks
Material review, founder conversations, evidence assessment and portfolio synthesis.
From SEK 150k
Designed for funds, accelerators, studios and innovation programmes.
NOT MENTOR SUPPORT
This is not pitch coaching, office hours or another layer of founder advice.
It is a structured assessment of whether each company has enough evidence, focus and operating discipline to justify its next commitment.
The purpose is not to judge founders from a distance. The purpose is to make the real constraint visible before the investor, programme or board spends more capital, time or attention in the wrong place.
Which companies deserve more capital, more support, a narrower plan — or a stop signal?
Start with a focused Portfolio Commercial Review discussion.
Jörn Green 